Roughly 53 million people aged 12 or older in the United States were classified as needing substance use treatment in 2024, based on the annual national survey conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). That figure includes alcohol and all illicit and prescription drugs. Of those 53 million, only about 10.2 million, or 19.3%, actually received any form of treatment during the year.
What the Numbers Include
The term “substance use disorder” covers a wide spectrum. Clinicians diagnose it using 11 criteria that fall into four categories: losing control over how much or how often you use, having your social life and responsibilities suffer, continuing to use in risky or harmful situations, and developing tolerance or withdrawal. Meeting just two or three of those criteria qualifies as a mild disorder. Six or more points to a severe one. So the 53 million figure captures everything from someone who repeatedly drinks more than they intend to and can’t cut back, all the way to someone injecting fentanyl daily and unable to hold a job.
That range matters because many people searching this question picture the most severe cases. The reality is that addiction exists on a continuum, and the majority of people with a diagnosable disorder are not homeless or visibly in crisis. Many are working, raising families, and hiding the problem from people close to them.
Opioids Remain the Deadliest Category
Opioid addiction drives the largest share of overdose deaths and economic damage. In 2023, illicit opioids, primarily fentanyl, cost the U.S. an estimated $2.7 trillion, according to a White House analysis. That’s equivalent to 9.7% of GDP. The cost breaks down into healthcare expenses (about $107 billion, or roughly $19,000 extra per year for each person with opioid use disorder compared to someone without it), lost workplace productivity ($107 billion from deaths, incarceration, and inability to work), and a much larger share tied to the value of lives lost prematurely.
There is some recent good news. Drug overdose deaths involving synthetic opioids like fentanyl dropped 35.6% between 2023 and 2024, falling from 22.2 deaths per 100,000 people to 14.3. Deaths involving prescription opioids like oxycodone and hydrocodone also fell about 21% over the same period. Provisional CDC data puts total U.S. drug overdose deaths at approximately 70,000 for the 12-month period ending in November 2025, a meaningful decline from the peak of over 100,000 annual deaths recorded just a few years earlier.
Stimulants Are a Growing Concern
Methamphetamine and cocaine addiction don’t get the same attention as opioids, but they affect millions. Among people with a stimulant use disorder in 2024, nearly half (48.3%) had a severe disorder, and another 28.5% had a mild one. That means only about one in four people addicted to stimulants fell into the moderate range. Stimulant addiction tends to cluster at the extremes: people are either in the early stages or deeply entrenched.
Stimulant overdose deaths have also been rising independently of opioids, though many fatal overdoses now involve both a stimulant and fentanyl. This “polysubstance” pattern, where people use multiple drugs simultaneously or unknowingly consume fentanyl mixed into other substances, complicates both prevention and treatment.
Young People and Addiction
About 1.6 million adolescents aged 12 to 17 and 8.2 million young adults aged 18 to 25 met criteria for a substance use disorder in the most recent comprehensive analysis. One notable shift: the old assumption that boys and young men are more likely to develop substance problems is no longer accurate. Among 12- to 17-year-olds, girls now have a higher rate of past-year substance use disorders (7.2%) than boys (5.5%). The gender gap has essentially inverted among teens.
The vast majority of adolescents and young adults with a substance use disorder do not receive treatment. This is consistent with the broader adult pattern, but the consequences of untreated addiction during critical brain development years can be especially long-lasting.
The Treatment Gap
The single most striking number in U.S. addiction data is the treatment gap. Four out of five people who need substance use treatment in a given year don’t get it. In 2024, that meant roughly 43 million people went without any professional help.
The reasons are layered. Cost and lack of insurance coverage remain barriers, but they’re not the only ones. Many people don’t believe they need treatment, or they fear the stigma attached to seeking it. Others live in areas with few providers, particularly rural counties where the nearest treatment facility may be hours away. Even among those who want help, wait times for programs that accept their insurance can stretch weeks or months, and for many types of addiction, that delay is enough for motivation to fade or for a fatal overdose to intervene.
How These Numbers Are Gathered
The primary source for U.S. addiction statistics is the National Survey on Drug Use and Health (NSDUH), conducted annually by SAMHSA. It surveys approximately 70,000 people aged 12 and older through in-person interviews. Participants answer sensitive questions on a tablet computer rather than out loud, which helps improve honesty, but the survey still has blind spots. It excludes people who are homeless and not in shelters, those who are incarcerated, and active-duty military, all populations with elevated rates of substance use. The true number of Americans with a substance use disorder is almost certainly higher than what the survey captures.
Overdose death data comes from the CDC’s National Vital Statistics System, which relies on death certificates. These counts are considered more reliable than self-reported survey data, though they only measure the most extreme outcome of addiction and miss the millions of people living with a disorder who haven’t overdosed.